[go: up one dir, main page]

AR039570A1 - Antagonistas de los receptores de trombina - Google Patents

Antagonistas de los receptores de trombina

Info

Publication number
AR039570A1
AR039570A1 ARP030101302A ARP030101302A AR039570A1 AR 039570 A1 AR039570 A1 AR 039570A1 AR P030101302 A ARP030101302 A AR P030101302A AR P030101302 A ARP030101302 A AR P030101302A AR 039570 A1 AR039570 A1 AR 039570A1
Authority
AR
Argentina
Prior art keywords
alkyl
group
independently selected
alkoxy
cycloalkyl
Prior art date
Application number
ARP030101302A
Other languages
English (en)
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29250954&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR039570(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of AR039570A1 publication Critical patent/AR039570A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Composiciones farmacéuticas que los contienen y un método para el tratamiento de enfermedades asociadas con trombosis, ateroesclerosis, restenosis, hipertensión, angina pectoris, arritmia, insuficiencia cardiaca, y cáncer administrando dichos compuestos. La terapia de combinación con otros agentes cardiovasculares es también reivindicada. Reivindicación 1: Un compuesto representado por la fórmula estructural (1), o una sal o solvato farmacéuticamente aceptable, en donde: la línea punteada simple representa un enlace simple opcional; y la línea punteada junto con la llena representa una doble ligadura opcional; n es 0-2; Q es una estructura del grupo de fórmulas (2), R1 es independientemente seleccionado del grupo consistente en H, alquilo (C1-6), fluoroalquilo (C1-6)-, difluoroalquilo (C1-6)-, trifluoro-alquilo (C1-6)-, cicloalquilo (C3-6), alquenilo (C2-6), hidroxi-alquilo (C1-6)-, y aminoalquilo (C1-6)-; R2 es independientemente seleccionado del grupo consistente en H, alquilo (C1-6), fluoroalquilo (C1-6)-, difluoroalquilo (C1-6)-, trifluoro-alquilo (C1-6)-, cicloalquilo (C3-6), alquenilo (C2-6), hidroxi-alquilo (C1-6)-, y aminoalquilo (C1-6)-; R3 es H, hidroxi, alcoxi (C1-6), -SOR16, -SO2R17, -C(O)OR17, -C(O)NR18R19, -alquilo (C1-6)-C(O)NR18R19, alquilo (C1-6), halógeno, fluoroalquilo (C1-6)-, difluoroalquilo (C1-6)-, trifluoroalquilo (C1-6)-, cicloalquilo (C3-6), cicloalquil (C3-6)-alquilo (C1-6)-, alquenilo (C2-6), ariloalquilo (C1-6)-, ariloalquenilo (C2-6)-, heteroariloalquilo (C1-6)-, heteroariloalquenilo (C2-6)-, hidroxialquilo (C1-6)-, -NR22R23R23, NR22R23-alquilo (C1-6)-, arilo, tioalquilo (C1-6)-, alquilo (C1-6)-tioalquilo (C1-6)-, alcoxi (C1-6)-alquilo (C1-6)-, NR18R19-C(O)-alquilo (C1-6)- o cicloalquilo (C3-6)-alquilo (C3-6)-; Het es heteroarilo un grupo mono- o bi-cíclico de 5 a 10 átomos comprendiendo de 1 a 9 átomos de carbono y 1 a 4 heteroátomos independientemente seleccionados del grupo consistente en N, O y S, donde un nitrógeno del anillo puede formar un N-oxido o un grupo cuaternario con un grupo alquilo (C1-4), donde Het está unido a B por un átomo de carbono miembro del anillo, y donde el grupo Het está substituido por W; W es 1 a 4 substituyentes independientemente seleccionados del grupo consistente en H, alquilo (C1-6), fluoroalquilo (C1-6)-, difluoroalquilo (C1-6)-, trifluoroalquilo (C1-6)-, cicloalquilo (C3-6), hidroxialquilo (C1-6)-, dihidroxialquilo (C1-6)-, NR25R26alquilo (C1-6)-, tioalquilo (C1-6)-, -OH, alcoxi (C1-6), halógeno, -NR4R5, -C(O)OR17, -COR16, alquiltio (C1-6)-, R21-arilo, R21-ariloalquilo (C1-6)-, arilo donde los carbonos adyacentes forman un anillo que comprende un grupo metilendioxi, y R21-heteroarilo; R4 y R5 son independientemente seleccionados del grupo consistente en H, alquilo (C1-6), fenilo, bencilo y cicloalquilo (C3-6), o R4 y R5 tomados juntos son -(CH2)4-, -(CH2)5- o -(CH2)2NR7-(CH2)2- y forman un anillo con el nitrógeno al cual ellos están unidos; R6 es H, alquilo (C1-6) o fenilo; R7 es H, alquilo (C1-6), -C(O)-R16, -C(O)OR17 o -SO2R17; R8, R10 y R11 son independientemente seleccionados del grupo consistente en R1 y -OR1, siempre que cuando el doble enlace opcional está presente, R10 está ausente; R9 es H, OH o alcoxi (C1-6); B es -(CH2)n3-, cis o trans -(CH2)n4CR12-CR12a(CH2)n5- o -(CH2)n4Cs(CH2)n5-, donde n3 es 0-5, n4 y n5 son independientemente 0-2, y R12 y R12a son independientemente seleccionados del grupo consistente en H, alquilo (C1-6) y halógeno; X es -O- o -NR6- cuando la línea punteada representa un enlace simple, o X es -OH o -NHR20 cuando el enlace está ausente; Y es =O, =S, (H, H), (H, OH) o (H, alcoxi (C1-6)) cuando la línea punteada representa un enlace simple, o cuando el enlace está ausente, Y es =O, (H, H), (H, OH), (H, SH) o (H, alcoxi(C1-6)); cada R13 es independientemente seleccionado de H, alquilo (C1-6), cicloalquilo (C3-8), -(CH2)n6NHC(O)OR16b, -(CH2)n6NHC(O)R16b, -(CH2)n6NHC(O)NR4R5, -(CH2)n6NHSO2R16, -(CH2)n6NHSO2NR4R5, y -(CH2)n6C(O)NR28R29 donde n6 es 0-4, haloalquilo, y halógeno; cada R14 es independientemente seleccionado entre H, alquilo (C1-6), -OH, alcoxi (C1-6), R27-ariloalquilo (C1-6), heteroarilo, heteroariloalquilo, heterociclilo, heterociclilalquilo, -(CH2)n6NHC(O)OR16b, -(CH2)n6NHC(O)R16b, -(CH2)n6NHC(O)NR4R5, -(CH2)n6NHSO2R16, -(CH2)n6NHSO2NR4R5, y -(CH2)n6C(O)NR28R29 donde n6 es 0-4, halógeno y haloalquilo; o R13 y R14 tomados juntos forman un anillo espirocíclico o heterospirociclico de 3-6 átomos; donde al menos uno de R13 o R14 es seleccionado del grupo consistente en -(CH2)n6NHC(O)OR16b, -(CH2)n6NHC(O)R16b, -(CH2)n6NHC(O)NR4R5, -(CH2)n6NHSO2R16, -(CH2)n6NHSO2NR4R5, y -(CH2)n6C(O)NR28R29 donde n6 es 0-4; R15 está ausente cuando la línea punteada representa un enlace simple y es H, alquilo (C1-6), -NR18R19, o -OR17 cuando el enlace está ausente; R16 es independientemente seleccionado del grupo consistente en alquilo (C1-6), fenilo y bencilo; R16b es H, alcoxi, alquilo (C1-6), alcoxi (C1-6)-alquilo (C1-6)-, R22-O-C(O)-alquilo (C1-6)-, cicloalquilo (C3-6), R21-arilo, R21-arilalquilo (C1-6), haloalquilo, alquenilo, halosubstituido alquenilo, alquinilo, alquinilo halosubstituido, R21-heteroarilo, R21-alquilo (C1-6) heteroarilo, R21-alquilo (C1-6) heterocicloalquilo, R28R29N-alquilo (C1-6), R28R29N-(CO)-alquilo (C1-6), R28R29N-(CO)O-alquilo (C1-6), R28O(CO)N(R29)-alquilo (C1-6), R28S(O)2N(R29)-alquilo (C1-6), R28R29N-(CO)-N(R29)-alquilo (C1-6), R28R2N-S(O)2N(R29)-alquilo (C1-6), R28-(CO)N(R29)-alquilo (C1-6), R28R29N-S(O)2-alquilo (C1-6), HOS(O)2-alquilo (C1-6), (OH)2P(O)2-alquilo (C1-6), R28-S-alquilo (C1-6), R28-S(O)2-alquilo (C1-6) o hidroxialquilo (C1-6); R17, R18 y R19 son independientemente seleccionados del grupo consistente en H, alquilo (C1-6), fenilo, y bencilo; R20 es H, alquilo(C1-6), fenilo, bencilo, -C(O)R6 o -SO2R6; R21 es 1 a 3 sustituyentes independientemente seleccionado del grupo consistente en H, -CN, -CF3, -OCF3, halógeno, -NO2, alquilo (C1-6), -OH, alcoxi (C1-6), alquilo (C1-6)amino-, di-(alquilo (C1-6))amino-, NR25R26-alquilo (C1-6)-, hidroxi-alquilo (C1-6)-, -C(O)OR17, -C(O)R17, -NHCOR16, -NHSO2R16, -NHSO2CH2CF3, -C(O)NR25R2, -NR25-C(O)-NR25R26, -S(O)R13, -S(O)2R13 y -SR13; R22 es H o alquilo (C1-6); R23 es H, alquilo (C1-6), -SO2R24, -C(O)NHR24 o -SO2NHR24; R24 es alquilo (C1-6), hidroxi alquilo (C1-6) o NR25R26-(alquilo (C1-6))-; R25 y R26 son independientemente seleccionados del grupo consistente en H y alquilo (C1-6); R27 es 1, 2 o 3 substituyentes seleccionados del grupo consistente en H, alquilo (C1-6), cicloalquilo (C3-6), alcoxi (C1-6), halógeno y -OH; y R28 y R29 son independientemente seleccionados del grupo consistente en H, alquilo (C1-6), alcoxi (C1-6), R27-ariloalquilo (C1-6), heteroarilo, heteroariloalquilo, hidroxialquilo (C1-6), alcoxi (C1-6)-alquilo (C1-6), heterociclilo, heterociclilalquilo, y haloalquilo; o R28 y R29 tomados juntos forman un anillo espirociclico o heterospirociclico de 3-6 átomos.
ARP030101302A 2002-04-16 2003-04-14 Antagonistas de los receptores de trombina AR039570A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37307202P 2002-04-16 2002-04-16

Publications (1)

Publication Number Publication Date
AR039570A1 true AR039570A1 (es) 2005-02-23

Family

ID=29250954

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030101302A AR039570A1 (es) 2002-04-16 2003-04-14 Antagonistas de los receptores de trombina

Country Status (33)

Country Link
US (3) US7304078B2 (es)
EP (5) EP1495018B3 (es)
JP (2) JP4558331B2 (es)
KR (1) KR101026929B1 (es)
CN (1) CN1659162B (es)
AR (1) AR039570A1 (es)
AT (3) ATE455774T1 (es)
AU (1) AU2003221932B2 (es)
BR (1) BRPI0309309B8 (es)
CA (1) CA2482858C (es)
CY (3) CY1107184T1 (es)
DE (3) DE60317493T3 (es)
DK (2) DK1495018T3 (es)
EC (1) ECSP045368A (es)
ES (3) ES2297150T7 (es)
FR (1) FR15C0047I2 (es)
IL (1) IL164585A (es)
LT (1) LTC1495018I2 (es)
LU (1) LU92759I2 (es)
MX (1) MXPA04010308A (es)
MY (1) MY144040A (es)
NL (1) NL300746I2 (es)
NO (2) NO330500B1 (es)
NZ (2) NZ575139A (es)
PE (1) PE20040412A1 (es)
PL (1) PL214718B1 (es)
PT (2) PT1495018E (es)
RU (2) RU2329264C9 (es)
SG (1) SG164279A1 (es)
SI (2) SI1495018T1 (es)
TW (1) TWI343919B (es)
WO (1) WO2003089428A1 (es)
ZA (1) ZA200408342B (es)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6346510B1 (en) 1995-10-23 2002-02-12 The Children's Medical Center Corporation Therapeutic antiangiogenic endostatin compositions
US7235567B2 (en) * 2000-06-15 2007-06-26 Schering Corporation Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist
US7488742B2 (en) * 2000-06-15 2009-02-10 Schering Corporation Thrombin receptor antagonists
US20040192753A1 (en) * 2000-06-15 2004-09-30 Samuel Chackalamannil Methods of use of thrombin receptor antagonists
CA2567981C (en) * 2004-05-28 2010-08-31 Schering Corporation Constrained himbacine analogs as thrombin receptor antagonists
JP2008515908A (ja) * 2004-10-06 2008-05-15 ユニバーシティー オブ ロチェスター 組織因子経路を阻害する薬剤を使用する、肺高血圧症の治療
ATE500249T1 (de) * 2005-01-14 2011-03-15 Schering Corp Synthese von himbacinanaloga
CA2594807A1 (en) * 2005-01-14 2006-07-20 Schering Corporation An exo-selective synthesis of himbacine analogs
CA2594871C (en) * 2005-01-14 2015-04-07 Schering Corporation Exo- and diastereo- selective syntheses of himbacine analogs
US7541471B2 (en) * 2005-01-14 2009-06-02 Schering Corporation Synthesis of himbacine analogs
MX2007008630A (es) * 2005-01-14 2007-09-12 Schering Corp Preparacion de alcohol propargilico quiral y ester intermediario de analogos de himbacina.
US7776889B2 (en) 2005-03-31 2010-08-17 Schering Corporation Spirocyclic thrombin receptor antagonists
US20070219154A1 (en) * 2005-12-20 2007-09-20 Suxing Liu Methods for preventing and/or treating a cell proliferative disorder
JP2009521472A (ja) * 2005-12-22 2009-06-04 シェーリング コーポレイション 心肺手術の合併症の予防としてのトロンビンレセプターアンタゴニスト
PE20080183A1 (es) * 2006-04-06 2008-03-10 Schering Corp Terapias de combinacion de tra
US8003803B2 (en) * 2006-04-13 2011-08-23 Schering Corporation Fused ring thrombin receptor antagonists
MX2009000107A (es) * 2006-06-29 2009-01-23 Schering Corp Antagonistas del receptor de trombina biciclicos y triciclicos sustituidos.
TWI367112B (en) * 2006-06-30 2012-07-01 Schering Corp Immediate-release tablet formulations of a thrombin receptor antagonist
AR061727A1 (es) * 2006-06-30 2008-09-17 Schering Corp Sintesis de dietil [[ 5- ( 3-fluorofenil) -piridin -2il] metil] fosfonato
DE102006036023A1 (de) 2006-08-02 2008-02-07 Sanofi-Aventis Imino-imidazo-pyridinderivate mit antithrombotischer Aktivität
TWI343262B (en) * 2006-09-26 2011-06-11 Schering Corp Rapidly disintegrating lyophilized oral formulations of a thrombin receptor antagonist
WO2008060372A2 (en) * 2006-10-04 2008-05-22 Schering Corporation Thrombin receptor antagonists based on the modified tricyclic unit of himbacine
WO2008042422A2 (en) * 2006-10-04 2008-04-10 Schering Corporation Bicyclic and tricyclic derivatives as thrombin receptor antagonists
JP2010513516A (ja) * 2006-12-22 2010-04-30 シェーリング コーポレイション 固形剤の湿式顆粒化処方物中の崩壊促進剤
BRPI0809095A2 (pt) * 2007-03-23 2014-09-09 Schering Corp Redução de eventos adversos após intervenção percutânea através de uso de um antagonista de receptor de trombina
MY148732A (en) 2008-02-05 2013-05-31 Sanofi Aventis Triazolium salts as par1 inhibitors, production thereof, and use as medicaments
MY152040A (en) 2008-02-05 2014-08-15 Sanofi Aventis Triazolopyridazines as par1 inhibitors, production thereof, and use as medicaments
WO2009124103A2 (en) * 2008-04-02 2009-10-08 Schering Corporation Combination therapies comprising par1 antagonists with par4 antagonists
TW201008930A (en) 2008-05-19 2010-03-01 Schering Corp Heterocyclic compounds as factor IXa inhibitors
JP5789256B2 (ja) 2009-06-04 2015-10-07 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． トロンビン受容体アンタゴニストの活性代謝物
WO2010144339A2 (en) 2009-06-08 2010-12-16 Schering Corporation A thrombin receptor antagonist and clopidogrel fixed dose tablet
EP2462123B1 (en) 2009-08-04 2013-10-02 Merck Sharp & Dohme Corp. 4,5,6-trisubstituted pyrimidine derivatives as factor ixa inhibitors
ES2527535T3 (es) 2010-04-16 2015-01-26 Sanofi Piridil-vinil-pirazolo-quinolinas como inhibidores de PAR1
EP2558465B1 (de) 2010-04-16 2014-12-17 Sanofi Trizyklische pyridyl-vinyl-pyrrole als par1-inhibitoren
KR101303348B1 (ko) 2010-06-25 2013-09-03 한국화학연구원 트롬빈 수용체 길항제인 ［6＋5］접합 바이사이클, 그의 제조방법 및 그를 포함하는 약제학적 조성물
US9340530B2 (en) 2012-03-06 2016-05-17 Merck Sharp & Dohme Corp. Preparation and use of bicyclic himbacine derivatives as PAR-1 receptor antagonists
US9604971B2 (en) 2013-07-22 2017-03-28 Aralez Pharmaceuticals Trading Dac Co-crystal of the PAR-1 receptor antagonists vorapaxar and aspirin
US9701669B2 (en) 2013-08-22 2017-07-11 Merck Sharp & Dohme Corp. Preparation and use of 7a-amide substituted- 6,6-difluoro bicyclic himbacine derivatives as PAR-1 receptor antagonists
WO2015026686A1 (en) * 2013-08-22 2015-02-26 Merck Sharp & Dohme Corp. 3'-pyridyl substituted- 6,6-difluoro bicyclic himbacine derivatives
WO2015026685A1 (en) 2013-08-22 2015-02-26 Merck Sharp & Dohme Corp. 7a-heterocycle substituted- 6, 6-difluoro bicyclic himbacine derivatives
FR3014693B1 (fr) 2013-12-16 2016-01-08 Pf Medicament Utilisation de la 3-(2-chloro-phenyl)-1-[4-(4-fluoro-benzyl)-piperazin-1-yl]-propenone pour la prevention et/ou le traitement des pathologies fonctionnelles pelvi-perineales
EP3131897B8 (en) 2014-04-16 2022-08-03 Merck Sharp & Dohme LLC Factor ixa inhibitors
DE102014108210A1 (de) 2014-06-11 2015-12-17 Dietrich Gulba Rodentizid
CN105985303B (zh) * 2015-02-13 2020-08-14 上海彩迩文生化科技有限公司 抗凝血剂的制备方法、中间体及其制备方法
CN106478608A (zh) * 2015-09-01 2017-03-08 博瑞生物医药（苏州）股份有限公司 沃拉帕沙的硫酸盐的结晶多晶型物
CN106749201A (zh) * 2015-11-25 2017-05-31 博瑞生物医药（苏州）股份有限公司 一种沃拉帕沙及其中间体的制备方法
WO2017134200A1 (en) * 2016-02-05 2017-08-10 Sanovel Ilac Sanayi Ve Ticaret A.S. A novel pharmaceutical composition of vorapaxar and metoprolol
TR201601548A2 (tr) * 2016-02-05 2018-03-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Vorapaksar ve metoprololün bi̇r farmasöti̇k kompozi̇syonu
WO2017181993A1 (zh) * 2016-04-22 2017-10-26 江苏天士力帝益药业有限公司 一种新的喜巴辛类似物及其在医药中的应用
CN106236779A (zh) * 2016-08-22 2016-12-21 孔五 一种脐带血富血小板血浆prp的制备方法
FR3090317B1 (fr) 2018-12-19 2021-05-07 Cvasthera Utilisation d’un antagoniste de par-1 pour le traitement d’une maladie inflammatoire chronique intestinale
CN110407819B (zh) * 2019-08-02 2020-06-26 牡丹江医学院 一种作为预防外科手术并发症的凝血酶受体拮抗剂
US20210113536A1 (en) * 2019-10-21 2021-04-22 United States Government as Represented by the Department of Veteran Affairs Methods and compositions for detecting and treating venous thromboembolism
FR3109089B1 (fr) 2020-04-08 2023-04-14 Cvasthera Composition pharmaceutique pour le traitement des maladies inflammatoires intestinales
CA3189771A1 (en) 2020-07-22 2022-01-27 Janssen Pharmaceutica Nv Compounds useful as factor xia inhibitors
US11845748B2 (en) 2021-03-18 2023-12-19 Janssen Pharmaceutica Nv Bicyclic pyridine N-oxide derivatives useful as a factor XIa inhibitors
US11919881B2 (en) 2021-03-18 2024-03-05 Janssen Pharmaceutica Nv Substituted pyridine N-oxide derivatives useful as a factor XIa inhibitors
US11814364B2 (en) 2021-03-18 2023-11-14 Janssen Pharmaceutica Nv Pyridine N-oxide derivatives useful as factor XIa inhibitors
EP4070658A1 (de) 2021-04-06 2022-10-12 BIORoxx GmbH Verwendung von blutgerinnungshemmenden verbindungen als rodentizide
US11897880B2 (en) 2021-04-30 2024-02-13 Janssen Pharmaceutica Nv 7,8-dihydrobenzo[e]pyrido[3,4-c]azocine-2,5(3H,6H)-dione derivatives useful as a factor XIa inhibitors
US11958856B2 (en) 2021-07-22 2024-04-16 Janssen Pharmaceutica Nv Substituted 1,2,3,8,9,9a-hexahydro-5H-pyrrolo[1,2-a]azepin-5-ones as factor XIa inhibitors
US12286429B2 (en) 2021-07-22 2025-04-29 Janssen Pharmaceutica Nv 5-oxo-1,2,3,5,8,8a-hexahydroindolizine-3-carboxamide derivatives useful as a factor XIa inhibitors
FR3134314A1 (fr) 2022-04-08 2023-10-13 Cvasthera Composition pharmaceutique à base de vorapaxar et son utilisation pour le traitement des maladies inflammatoires intestinales

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2623810B2 (fr) 1987-02-17 1992-01-24 Sanofi Sa Sels de l'alpha-(tetrahydro-4,5,6,7 thieno(3,2-c) pyridyl-5) (chloro-2 phenyl) -acetate de methyle dextrogyre et compositions pharmaceutiques en contenant
TW197435B (es) * 1990-11-22 1993-01-01 Takeda Pharm Industry Co Ltd
GB9102862D0 (en) * 1991-02-11 1991-03-27 Erba Carlo Spa N-imidazolyl derivatives of substituted or alkoxymino tetrahydronaphthalenes and chromans
IL106197A (en) 1992-07-30 1999-11-30 Cor Therapeutics Inc Agagonists for the rhombin receptors and pharmaceutical preparations containing them
US5576328A (en) 1994-01-31 1996-11-19 Elf Sanofi Method for the secondary prevention of ischemic events
SK285153B6 (sk) * 1997-11-25 2006-07-07 Schering Corporation Heterocyklickou skupinou substituovaná tricyklická zlúčenina, farmaceutický prostriedok obsahujúci túto zlúčeninu a jej použitie
US6063847A (en) 1997-11-25 2000-05-16 Schering Corporation Thrombin receptor antagonists
FR2779726B1 (fr) 1998-06-15 2001-05-18 Sanofi Sa Forme polymorphe de l'hydrogenosulfate de clopidogrel
CZ20024098A3 (cs) * 2000-06-15 2003-05-14 Schering Corporation Látky, antagonizující receptor thrombinu
US20040192753A1 (en) * 2000-06-15 2004-09-30 Samuel Chackalamannil Methods of use of thrombin receptor antagonists
US7488742B2 (en) * 2000-06-15 2009-02-10 Schering Corporation Thrombin receptor antagonists
MY139335A (en) * 2001-10-18 2009-09-30 Schering Corp Substituted tricyclic himbacine derivatives that are useful as thrombin receptor antagonists

Also Published As

Publication number Publication date
RU2329264C2 (ru) 2008-07-20
BRPI0309309B8 (pt) 2021-05-25
ATE455774T1 (de) 2010-02-15
ZA200408342B (en) 2006-05-31
NL300746I1 (es) 2016-01-21
ES2297150T7 (es) 2012-03-16
TW200404068A (en) 2004-03-16
JP2005528406A (ja) 2005-09-22
NZ535880A (en) 2007-11-30
EP1982984A3 (en) 2008-10-29
HK1123302A1 (en) 2009-06-12
RU2008106401A (ru) 2009-08-27
KR20040099441A (ko) 2004-11-26
LTC1495018I2 (lt) 2017-04-10
PL373332A1 (en) 2005-08-22
US20070270439A1 (en) 2007-11-22
EP1860106B1 (en) 2010-01-20
US20070179187A1 (en) 2007-08-02
JP4558331B2 (ja) 2010-10-06
ES2357876T3 (es) 2011-05-03
PT1495018E (pt) 2008-02-19
ES2297150T3 (es) 2008-05-01
HK1070887A1 (en) 2005-06-30
ECSP045368A (es) 2005-01-03
EP1495018B1 (en) 2007-11-14
BR0309309A (pt) 2005-02-15
DE60335679D1 (de) 2011-02-17
CY1111363T1 (el) 2015-08-05
US20030216437A1 (en) 2003-11-20
ATE494284T1 (de) 2011-01-15
ATE378330T1 (de) 2007-11-15
ES2338171T3 (es) 2010-05-04
NO2015016I2 (no) 2015-07-09
CY2015029I1 (el) 2016-04-13
WO2003089428A1 (en) 2003-10-30
IL164585A (en) 2010-11-30
PT2065384E (pt) 2011-03-16
NZ575139A (en) 2010-08-27
AU2003221932A1 (en) 2003-11-03
MY144040A (en) 2011-07-29
PE20040412A1 (es) 2004-07-12
EP2065384A1 (en) 2009-06-03
SI2065384T1 (sl) 2011-05-31
CY2015029I2 (el) 2016-04-13
LU92759I2 (en) 2015-08-31
NO20044963L (no) 2004-11-15
CY1107184T1 (el) 2012-10-24
FR15C0047I2 (fr) 2016-05-06
CA2482858A1 (en) 2003-10-30
HK1129893A1 (en) 2009-12-11
DE60317493D1 (en) 2011-01-13
NL300746I2 (es) 2016-01-21
CA2482858C (en) 2010-11-30
AU2003221932B2 (en) 2007-11-22
SG164279A1 (en) 2010-09-29
IL164585A0 (en) 2005-12-18
US7304078B2 (en) 2007-12-04
SI1495018T1 (sl) 2008-04-30
EP1982984B1 (en) 2013-02-13
CN1659162B (zh) 2011-08-31
EP2062890A1 (en) 2009-05-27
DE60317493T3 (de) 2018-07-12
EP2062890B1 (en) 2011-01-05
DE60331114D1 (de) 2010-03-11
PL214718B1 (pl) 2013-09-30
DK2065384T3 (da) 2011-05-02
CN1659162A (zh) 2005-08-24
DK1495018T3 (da) 2008-02-18
FR15C0047I1 (es) 2015-08-28
MXPA04010308A (es) 2005-02-03
JP2010132710A (ja) 2010-06-17
NO330500B1 (no) 2011-05-02
EP2065384B1 (en) 2011-01-05
RU2004133375A (ru) 2005-07-10
US7713999B2 (en) 2010-05-11
BRPI0309309B1 (pt) 2018-09-04
NO2015016I1 (no) 2015-07-20
EP1495018A1 (en) 2005-01-12
RU2329264C9 (ru) 2009-04-20
EP1982984A2 (en) 2008-10-22
KR101026929B1 (ko) 2011-04-04
DE60317493T2 (de) 2008-09-18
TWI343919B (en) 2011-06-21
EP1860106A1 (en) 2007-11-28
EP1495018B3 (en) 2011-03-16

Similar Documents

Publication Publication Date Title
AR039570A1 (es) Antagonistas de los receptores de trombina
AR084768A1 (es) Moduladores de la senda de complemento y usos de los mismos
JP2008526999A5 (es)
AR068496A1 (es) Piperidinas sustituidas, una composicion farmaceutica que las comprende y su uso para el tratamiento de enfermedades mediadas por la modulacion de la actividad de gpr119.
PE20050963A1 (es) Compuestos derivados de 8-azoniabiciclo [3.2.1]octanos como antagonistas de receptores de acetilcolina muscarinicos
AR036832A1 (es) Compuestos derivados de himbacina, agonistas receptores de trombina, composiciones farmaceuticas y el uso de dichos compuestos para la preparacion de medicamentos
AR044543A1 (es) Derivados de pirazolo-quinazolina, un procedimiento para su preparacion y su uso como inhibidor de quinasa
AR046711A1 (es) 5-7-diaminopirazolo[4,3d]pirimidinas como inhibidores de la pde-5,composiciones farmaceuticas que las contienen y usos en el tratamiento de hipertensiones
CO5640047A2 (es) Acidos fenoxiaceticos sustituidos como compuestos farmaceuticos utiles para el trtamiento de desordenes respiratorios, las composiciones farmaceuticas que los contienen y los procesos para su preparacion
RU2008142600A (ru) Органическое соединение
AR048341A1 (es) Moduladores cannabinoides de tetrahidro-indazol
AR049399A1 (es) Difenilimidazopirimidina e -imidazol aminas como inhibidores de b-secretasa y metodo de obtencion de los mismos
AR036044A1 (es) Compuestos piranoindazoles, composiciones farmaceuticas y su uso para la manufactura de un medicamento para el tratamiento del glaucoma
AR071592A1 (es) Fenoxibenzamidas sustituidas
AR053652A1 (es) Derivados de indol como inhibidores de proteina quinasas. composiciones farmaceuticas
AR035812A1 (es) Compuestos de acrilamida farmaceuticamente efectivos como inhibidores de la enoil-acp reductasa-fabi-; composiciones formuladas con dichos compuestos, metodo para inhibir dicha reductasa , respectivamente, para tratar infecciones bacterianas utilizando dichos compuestos y uso de los compuestos menci
RU93058534A (ru) Применение производных тетрагидрокарбазола в качестве антагонистов 5-нт*001 рецептора, производные тетрагидрокарбазола, способ их получения, способ лечения и фармацевтическая композиция
RU2011101140A (ru) Пирроло[2,3-b]пиридиновые производные в качестве ингибиторов протеинкиназ
CL2009000127A1 (es) Compuestos derivados de [indol, azaindol]-2-carboxamida sustituidos con un grupo silanilo; procedimiento de preparacion; compuestos intermediarios; composicion farmaceutica; y su uso en el tratamiento del dolor, inflamacion, trastornos metabolicos, entre otras enfermedades mediadas por la modulacion del receptor trpv1.
MX2009003761A (es) Derivados biciclicos y triciclicos como antagonistas del receptor de trombina.
NO20072609L (no) Malonamid-derivater
AR053566A1 (es) Compuestos espiriciclicos antagonistas de los receptores de trombina
AR082075A1 (es) Derivados de dioxima eter microbicidas
AR053092A1 (es) Compuestos derivados de acido fenoxiacetico y compuestos intermediarios de sintesis
AR051334A1 (es) Derivados de 2- amido-4-feniltiazol

Legal Events

Date Code Title Description
FG Grant, registration